A Phase 2 Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line Treatment of Patients with Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)

Clinical Trial Grant

Duke Scholars

Principal Investigator Neal Edward Ready Medicine, Medical Oncology

Administered By

Duke Cancer Institute

Awarded By

Stem CentRx, Inc.

Start Date

March 1, 2016

End Date

September 17, 2020

Administered By

Duke Cancer Institute

Awarded By

Stem CentRx, Inc.

Start Date

March 1, 2016

End Date

September 17, 2020